The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Obesity-associated cancers tripled nationwide over past two decades

2.

Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials

3.

Detecting pancreatic cancer through changes in body composition and metabolism

4.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

5.

Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot